Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
Phase 1
Terminated
- Conditions
- Non Hodgkin LymphomaSolid Tumor
- Interventions
- Biological: ADG106 injectionBiological: PD-1 antibody injection
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Adagene (Suzhou) Limited
- Target Recruit Count
- 25
- Registration Number
- NCT04775680
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Adagene (Suzhou) Limited
- Target Recruit Count
- 62
- Registration Number
- NCT03802955
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Shanghai Dongfang Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath